anti c kit antibody drug conjugate lop628

Drug Overview

The medication known as anti c kit antibody drug conjugate lop628 (also identified as AMG 820) is an investigational, high-precision immunotherapy designed to target the “protective shield” that tumors build to hide from the immune system. It is a fully human monoclonal antibody that acts as a potent inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1R), also known as c-fms.

Developed by Amgen, AMG 820 is part of a strategic class of “Microenvironment Modulators.” Rather than attacking cancer cells directly, it is engineered to shut down the signals that recruit immunosuppressive cells to the tumor site. By “cleaning up” the tumor neighborhood, AMG 820 aims to allow the body’s natural defenses to recognize and destroy the cancer.

• Generic Name: Anti-c-fms monoclonal antibody AMG 820.
• Drug Class: Fully Human IgG2 Monoclonal Antibody / CSF1R Inhibitor.
• Target: c-fms (CSF1R / Colony-Stimulating Factor 1 Receptor).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Discontinued. As of 2026, AMG 820 is no longer in active clinical development. While it completed Phase I trials, the drug has been discontinued in favor of newer-generation CSF1R inhibitors that offer better potency or combination potential.

What Is It and How Does It Work? (Mechanism of Action)

The c-fms/CSF1R Pathway

The c-fms receptor is a protein found on the surface of specific immune cells, particularly macrophages. Cancer cells secrete a signal called CSF1, which acts like a “siren,” calling these macrophages into the tumor. Once inside, these cells transform into Tumor-Associated Macrophages (TAMs). These TAMs don’t fight the cancer; instead, they help it grow new blood vessels and shut down attacking T-cells.

Molecular Level Mechanisms

1. Competitive Inhibition: After infusion, AMG 820 travels through the blood and binds with high affinity to the extracellular domain of the c-fms receptor.
2. Ligand Blockade: By “clamping” onto the receptor, the antibody prevents the natural signals (CSF1 and IL-34) from attaching. This effectively cuts off the communication line between the cancer and the immune system.
3. Depletion of TAMs: Without the CSF1 signal, macrophages cannot survive or migrate into the tumor. Research has shown that AMG 820 can significantly reduce the number of these “traitorous” immune cells within the tumor tissue.
4. Reprogramming the Microenvironment: By removing the suppressive TAMs, AMG 820 helps “re-activate” the tumor environment, potentially making the cancer much more vulnerable to other treatments like chemotherapy or T-cell therapies.
5. Inhibition of Osteoclasts: Because c-fms is also found on osteoclasts (cells that break down bone), AMG 820 can stop cancer from “eating” into the bone, a common problem in advanced prostate and breast cancers.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for AMG 820.

During its clinical development, it was investigated in Phase I studies (such as NCT01444404) for:

• Advanced Solid Tumors: Including cancers of the lung, breast, and colon that had failed standard treatments.
• Metastatic Malignancies: Targeting the role of TAMs in promoting the spread of cancer.

Dosage and Administration Protocols

Because this agent was discontinued, there is no established “standard” dose. The following information is based on the Phase I dose-escalation research.

Clinical Efficacy and Research Results

The clinical results for AMG 820 defined the future of “macrophage-targeting” therapy.

• Safety & Tolerability: Phase I results confirmed that AMG 820 was generally safe and successfully reached its target in the body.
• Pharmacodynamic Proof: Biopsy data from trial participants showed a measurable reduction in the number of CD163+ macrophages within the tumors, proving that the drug’s mechanism of action worked in humans.
• Clinical Limitations: While the drug was safe and hit its target, it did not produce enough “objective responses” (tumor shrinkage) as a single agent. This led to the conclusion that CSF1R inhibitors like AMG 820 are best used in combination with other drugs, rather than alone.

Safety Profile and Side Effects

As a targeted antibody, AMG 820 avoids the harsh side effects of chemotherapy, but it has a very specific set of side effects related to its effect on healthy macrophages.

Common Side Effects (>10%):

• Periorbital Edema: Swelling around the eyes (a “class effect” of CSF1R inhibitors).
• Fatigue: A general sense of tiredness.
• Nausea/Vomiting: Usually mild.
• Pruritus: Itching of the skin.

Serious Adverse Events:

• Elevated Liver Enzymes: Temporary spikes in AST/ALT, requiring regular blood monitoring.
• Infusion-Related Reactions: Fever, chills, or rash during the IV process.
• CK Elevation: Increases in Creatine Kinase, indicating potential muscle stress.

Research Areas

In the field of Stem Cell and Regenerative Medicine, the c-fms receptor is highly significant because it is a marker for certain monocyte-derived stem cells. Researchers are using the data from AMG 820 to study how “reprogramming” the immune environment can help healthy stem cells repair tissues after cancer treatment. By temporarily silencing the CSF1R pathway, scientists hope to learn how to guide the body’s regenerative cells to heal bone and lung tissue more effectively.

Patient Management and Practical Recommendations

Pre-treatment Tests (Historically Required):

• Baseline Eye Exam: To monitor for the specific “eye swelling” side effect.
• Liver Function Tests (LFTs): Essential to ensure the liver can process the treatment.
• Tumor Biopsy: Often used to check the baseline levels of macrophages.

Precautions:

• Facial Swelling: Patients should be warned that swelling around the eyes is common but usually temporary and not dangerous.
• Liver Health: Avoid heavy alcohol use while on medications that affect the liver enzymes.

“Do’s and Don’ts” List:

• DO report any sudden weight gain or facial swelling to your oncology team.
• DO stay hydrated, as this can help manage mild fatigue and itching.
• DON’T miss scheduled blood draws; these are the only way to track liver health during treatment.
• DON’T ignore a fever over 100.4°F (38°C), as this could be an infusion reaction or sign of infection.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. AMG 820 is an investigational agent that has been discontinued from active clinical development. It is not approved by the US Food and Drug Administration (FDA) for any indication. Always consult with a qualified oncologist regarding currently available and approved treatments for your condition.